NextCure is a biopharmaceutical company focused on discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Co.'s product candidates include: NC410, which is a fusion protein of LAIR-2, a naturally occurring soluble version of and decoy protein for Leukocyte Associated Immunoglobulin Like Receptor 1 (LAIR-1) and is designed to block immune suppression mediated by LAIR-1; NC762, which is a monoclonal antibody that binds specifically to human B7 homolog 4 protein, a protein expressed on multiple tumor types; and NC525 (LAIR-1 mAb), which selectively targets Acute Myeloid Leukemia, blast cells and leukemic stem cells. The NXTC YTD return is shown above.
The YTD Return on the NXTC YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether NXTC YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the NXTC YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|